1 Mild induced hypothermia: Effects on sepsis-related coagulopathy - Results from a randomized controlled trial. ME Johansen, JU Jensen, MH Bestle, SR Ostrowski, K Thormar, H Christensen, HP Pedersen, L Poulsen, T Mohr, J Kjær, A Cozzi-Lepri, K Møller, E Tønnesen, JD Lundgren, PI Johansson.
Thrombosis Research. 2015 ;135(1):175-82. abstract  (IF: 2.427)
 

2 Profound endothelial damage predicts impending organ failure and death in sepsis. ME Johansen,  PI Johansson, SR Ostrowski, MH Bestle, L Hein, ALG Jensen, P Søe-Jensen, MH Andersen, M Steensen, T Mohr, K Thormar, B Lundgren, A Cozzi-Lepri, JD Lundgren, JU Jensen.

Seminars of Thrombosis and Haemostasis. 2015;41(1):16-25. abstract (IF: 3.693)
 

3 Readmission after intensive care - frequent, hazardous and possibly preventable. TS Itenov, JU Jensen.
Critical Care Medicine. 2015;43(2):504-505. abstract  (IF: 6.147)

4 Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. C Marzolini, C Sabin, F Raffi, M Siccardi, C Mussini, O Launay, D Burger, B Roca, J Fehr, S Bonora, A Mocroft, N Obel, FA Dauchy, R Zangerle, C Gogos, N Gianotti, A Ammassari, C Torti, J Ghosn, G Chêne, J Grarup, M Battegay; for the Efavirenz, Obesity Project Team the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
AIDS. 2015;29(2):193-200. abstract (IF: 6.557)
 

5 Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based antiretroviral therapy: A multi-cohort European case-control study using centralized ultrasensitive 454 pyrosequencing. A Cozzi-Lepri, M Noguera-Julian, F Di Giallonardo, R Schuurman, M Däumer, S Aitken, F Ceccherini-Silberstein, A d'Arminio Monforte, A Geretti, C Booth, R Kaiser, C Michalik, K Jansen, P Bellecave, B Masquelier, R Kouyos, E Castro, H Furrer, A Schultze, H Günthard, F Brun-Vézinet, R Paredes, K Metzner. 
Journal of Antimicrobial Chemotherapy. (2015)70 (3): 930-940. abstract (IF: 5.439)
 

6 Invasive candida infections and the harm from antibacterial drugs in critically ill patients - Data from a randomised, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem and cefuroxime.  JU Jensen, L Hein, B Lundgren, MH Bestle, T Mohr, MH Andersen, J Løken, H Tousi, P Søe-Jensen, AØ Lauritsen, D Strange, JA Petersen, K Thormar, KM Larsen, NE Drenck, J Helweg-Larsen, ME Johansen, K Reinholdt, JK Møller, B Olesen, MC Arendrup, C Østergaard, A Cozzi-Lepri, J Grarup, JD Lundgren. 
Critical Care Medicine. 2015;43(3):594-602. (IF: 6.147)
 

7 Cancer risk and use of protease inhibitor or non-nucleoside reverse transcriptase inhibitor based combination antiretroviral therapy: the D:A:D study. M Bruyand, L Ryom, L Shepherd, G Fätkenheuer, A Grulich, P Reiss, S De Wit, A d’Arminio Monforte, H Furrer, C Pradier, J Lundgren, C Sabin for the D:A:D Study Group. 
Journal of AIDS. 2015; 68(5):568-77. (IF: 0.608)

8 Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. A Mocroft, JD Lundgren, M Ross, M Law, P Reiss, O Kirk, C Smith, D Wentworth, J Neuhaus, CA Fux, O Moranne, P Morlat, MA Johnson, L Ryom, D:A:D Study Group, The Royal Free Hospital Clinic Cohort, The INSIGHT, SMART and ESPRIT Syudt Groups.
PLOS Medicine, 2015.

9 Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. GV Matthews, J Neuhaus, S Bhagani, SH Mehta, E Vlahakis, M Doroana, S Naggie, A Arenas-Pinto, L Peters, JK Rockstroh, International Network for Strategic Initiatives in Global HIV Trial (INSIGHT) START Study Group.
HIV Medicine. 2015, Suppl 1:129-36. (IF: 3.454). abstract

10 Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA cohort. D. Podlekareva, D Grint, I. Karpov, A. Rakmanova, K Mansinho, N. Chentsova, I. Zeltina, M. Losso, M. Parczewski J. D. Lundgren, A. Mocroft, O. Kirk for EuroSIDA
EuroCoord. HIV Medicine. 2015  abstract 

11 Major differences in organisation and availability of health care and medicines for HIV/TB coinfected patients across Europe. Mansfeld M, Skrahina A, Shepherd L, Schultze A, Panteleev AM, Miller RF, Miro JM, Zeltina I, Tetradov S, Furrer H, Kirk O, Grzeszczuk A, Bolokadze N, Matteelli A, Post FA, Lundgren JD, Mocroft A, Efsen A, Podlekareva DN for the TB:HIV study group in EuroCoord. 
HIV Medicine. 2015;16(9):544-52.  (IF: 3.454)  abstract

12 Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, The INSIGHT START Study Group, J.D. Lundgren, A.G. Babiker , F. Gordin, S. Emery, B. Grund, S. Sharma, A. Avihingsanon, D.A. Cooper, G. Fätkenheuer, J.M. Llibre, J. Molina, P. Munderi, M. Schechter, R. Wood, K.L. Klingman, S. Collins, H.C. Lane, A.N. Phillips, J.D. Neaton, The INSIGHT START Study Group 
The New England Journal of Medicine 2015  article

13 Factors associated with plasma IL-6 during HIV infection. Borges ÁH, O'Connor JL, Phillips AN, Rönsholt FF, Pett S, Vjecha MJ, French MA, Lundgren JD; INSIGHT SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee
Journal Infectious Diseases 2015;212(4):585-95. article

14 Roundtable discussion on the Third Global Symposium on Health Systems Research: why prioritise talk over aid in the midst of the Ebola crisis? JV Lazarus, D Balabanova, K Safreed-Harmon, K Daniels, KM Mabaso, M McKee, T Mirzoev, AA Hyder, S Gruskin.
BMC Health Services Research. 2015;15(1):192. article

15 The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. C Beyrer, D.L. Birx, LG. Bekker, F. Barré-Sinoussi, P. Cahn, M.R.Dybul, S.P. Eholié, M.M. Kavanagh, E.T. Katabira, J.D. Lundgren, L. Mworeko, M. Pala, T. Puttanakit, O. Ryan, M. Sidibé, J. Montaner
The Lancet 2015, Vol 386(9993): 505-7, (IF: 45.22). article

16 Projected Lifetime Healthcare Costs Associated with HIV Infection. F.Nakagawa, A. Miners, C.J. Smith, R.D. Simmons, R. K. Lodwick, V. Cambiano, J.D. Lundgren, V. Delpech, A.N. Phillips
PLoS One 2015, article 10(4), e0125018. (IF: 3.23) article

17 Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. J.D. Baxter, D. Dunne, E. White, S. Sharma, A.M. Geretti, M.J. kozal, M.A. Johnson, S. Jacoby, J.M. Libre, J. Lundgren, and the International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.
HIV Medicine 2015, 16 Suppl 1: 77-87.(IF:3.45 ) abstract

18 Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.  S. Sharma, A.G. Babiker, S. Emery, F.M. Gordin, J.D. Lundren, J.N. Neaton, E. Bakowska, M. Schechter, M.J. Wiselka, M.J. Wolff, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.
HIV Medicine. 2015, suppl 1:30-6  (IF:3.45 ) abstract

19 Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. J. Vingerhoets, V. Calvez, P. Flandre, A.G. Marcelin, F. Ceccherini-Silberstein, D.F: Perno, M.M. Santoro, R. Bateson, M. Nelson, A. Cozzi-lepri, J. Grarup, J. Lundgren, F. Incardona, R. Kaiser, A. Sonnerborg, B. Clotet, R. Paredes, H.F. Günthard, B. Ledergerber, A. Hoogstoel, S. Nijs, L. Tambuyzer, L. Lavreys, M. Opsomer and on behalf of the Etravirine Cohort Study Group
HIV Medicine 2015 16(5): 297-306 (IF: 3.45). abstract

20 Epidemiology of hepatitis C virus in HIV-infected patients. Peters L, Klein MB. 
Current Opinion in HIV & AIDS. 2015;10(5):297-302. abstract

21 Liver-related death among HIV/HCV coinfected individuals, implications for the era of directly acting antivirals. D Grint, L Peters, JK Rockstroh, A Rakmanova, T Trofimova, K Lacombe, I Karpov, M Galli, P Domingo, O Kirk, JD Lundgren, A. Mocroft for EuroSIDA in EuroCoord.
AIDS. 2015 ;29(10):1205-15. (IF: 6.348) abstract

22 Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? C. Boesecke, D. Grint, V. Soriano, J.D. Lundgren, A. d'Arminio Monforte, V.M. Mitsura, N. Chentsova, V. Hadziosmanovic, O. Kirk, A. Mocroft, L. Peters, J. Rockstroh for EuroSIDA in EuroCoord.
Liver International. 2015 ;35(11):2384-91.  (IF: 4.41) abstract

23 Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study. D Raben, A Mocroft, M Rayment, VM Mitsura, V Hadziosmanovic, ZM Sthoeger, A Palfreeman, S Morris, G Kutsyna, A Vassilenko, J Minton, C Necsoi, VP Estrada, A Grzeszczuk, VS Johansson, J Begovac, EL Ong, A Cabié, F Ajana, BM Celesia, F Maltez, M Kitchen, L Comi, UB Dragsted, N Clumeck, J Gatell, B Gazzard, A d'Arminio Monforte, J Rockstroh, Y Yazdanpanah, K Champenois, ML Jakobsen, A Sullivan, JD Lundgren, HIDES Audit Study Group. 
PLOS One 2015  (IF: 3.234) abstract

24 Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study, 2010 to 2013. The Late Presenters Working Group for COHERE in EuroCoord.
Euro Surveillance. 2015;20(47). abstract

25  Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative study. The Migrants Working Group on behalf of COHERE in EuroCoord. 
Lancet HIV. 2015 ;2(12):e-540-9. abstract

26 Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients: COHERE in EuroCoord. Hepatitis C Working Group for COHERE in EuroCoord. 
BMC Infectious Diseases. 2015 4;15:498. abstract

27 HIV resistance testing and detected drug resistance in Europe: Data from the EuroSIDA cohort 1997-2012. A Schultze, AN Phillips, R Paredes, M BAttegay, JK Rockstroh, L Machala, J Tomazic, PM Girard, I Januskevica, K Gronborg-Laut, JD Lundgren, A Cozzi-Lepri for EuroSIDA in EuroCoord.
AIDS. 2015 ;29(11):1379-89. (IF: 6.348)

28 Clinical Application of Variation in Replication Kinetics during Episodes of Post-Transplant Cytomegalovirus Infections. Lodding IP et al. 
EBioMedicine 2015 ;2(7):699-705. article

29 Major challenges in clinical management of TB/HIV coinfected patients in Eastern Europe compared with Western Europe and Latin America. Anne Marie W. Efsen, Anna Schultze, Frank A. Post, Alexander Panteleev, Hansjakob Furrer, Robert F. Miller, Marcelo H. Losso, Javier Toibaro, Aliaksandr Skrahin, Jose M. Miro, Joan A. Caylà, Enrico Girardi, Mathias Bruyand, Niels Obel, Daria N. Podlekareva, Jens D. Lundgren, Amanda Mocroft, Ole Kirk on behalf of the TB:HIV study group in EuroCoord.
PLoS One. 2015 30;10(12): article (IF:3.234)

30 Sustainable HIV treatment in Africa through viral-load-informed differentiated care. A Phillips, A Shroufi, L Vojnov, J Cohn, T Roberts, et al., The Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa.
Nature. 2015;528(7580):S68-76. (IF: 41.5) abstract

31 The Global Fund to Fight AIDS, Tuberculosis and Malaria's investments in harm reduction through the rounds-based funding model (2002–2014). J Bridge, BM Hunter, E Albers,C Cook ,M Guarinieri,JV Lazarus,J MacAllister,S  McLean,D Wolfe.
International Journal of Drug Policy 2015. abstract

32 Changes in public attitudes towards confidential adolescent sexual and reproductive health services in Lithuania: findings from the cross-sectional surveys conducted in 2005 and 2012. L Jaruseviciene, A  Zaborskis, S Sauliune,G Jarusevicius, JV Lazarus.
BMC Health Services Research 2015;15:360. abstract

33 Trombocytopenia and cancer risk during HIV infection. A.H. Borges, J.D. Lundgren, A. Mocroft.
AIDS. 2015;29(11):1425-7. abstract